Milestone Scientific Overview
Valuation check: MLSS's ROE is -119.38%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow-119.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Milestone Scientific (MLSS) currently reports a ROE of -119.38%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Milestone Scientific's ROE history and peer comparisons.
Milestone Scientific's ROE of -119.38% is lower than the Healthcare sector average of 11.15%. That is roughly 1170.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Milestone Scientific's current -119.38% should be judged against Healthcare norms (sector average: 11.15%) and against MLSS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -119.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Milestone Scientific, and consider following MLSS for alerts when major investors trade the stock.
Milestone Scientific is classified in the Healthcare sector. On ROE, it currently shows -119.38% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MLSS with unrelated industries.
